The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.

Autor:	Komlodi-Pasztor E; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, United States., Escarra-Senmarti M; Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Bazer DA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Bhatnagar A; Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, United States., Perez Heydrich CA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Messmer M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States., Ambinder RF; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Gladstone DE; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Northwell Health Cancer Institute, New Hyde Park, NY, United States., Clayton L; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Goodrich A; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Schoch L; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Wagner-Johnston N; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., VandenBussche CJ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Huang P; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Holdhoff M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Rosario M; Department of Pathology, Division of Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Sep 04; Vol. 15, pp. 1433442. Date of Electronic Publication: 2024 Sep 04 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1433442
Abstrakt:	The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination is extremely important for lymphoma patients because they tend to be elderly with comorbidities which leaves them at increased risk of poor outcomes once infected by Coronavirus. Anti-CD20 therapies such as rituximab, deplete B-cell populations and can affect vaccine efficacy. Therefore, a knowledge of the effect of COVID-19 vaccination in this group is critical. We followed a cohort of 28 patients with CD20-positive lymphomatous malignancies treated with rituximab that started prior to their course of COVID-19 vaccination, including boosters. We assayed for vaccine "take" in the humoral (IgG and IgA) and cellular compartment. Here, we show that short-term and long-term development of IgG and IgA antibodies directed toward COVID-19 spike protein are reduced in these patients compared to healthy controls. Conversely, the robustness and breath of underlying T-cell response is equal to healthy controls. This response is not limited to specific parts of the spike protein but spans the spike region, including response to the conserved Receptor Binding Domain (RBD). Our data informs on rational vaccine design and bodes well for future vaccination strategies that require strong induction of T-cell responses in these patients. Competing Interests: MH: Advisory Board: Servier, Novartis, AnHeart, Bayer; Steering Committee: Novartis; Honoraria for educational talks: Pfizer (educational talk for Pfizer staff in 2021), Novartis; Data Safety Monitoring Board: Advarra, Parexel. MR: Patent applications have been filed and are currently pending in US, US-2023-0372469, and Europe, EP 4228686 for a T cell vaccine for SARS virus. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Komlodi-Pasztor, Escarra-Senmarti, Bazer, Bhatnagar, Perez Heydrich, Messmer, Ambinder, Gladstone, Clayton, Goodrich, Schoch, Wagner-Johnston, VandenBussche, Huang, Holdhoff and Rosario.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu